Preclinical data updates for early-stage programs (EVX-V1) are low-impact catalysts at a $26M market cap. The stock may see minimal short-term movement from this scientific conference presentation. Monitor for next clinical-stage milestone (e.g., Phase 1 initiation or IND filing) or partnership news for meaningful re-rating.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 13 $3.02entry
- T+1 · 4mo ago +0.33%α −0.02% · $3.03
- T+5 · 4mo ago +1.82%α +2.61% · $3.08
- T+20 · 3mo ago +0.99%α −2.19% · $3.05
- T+60 · 6w ago +4.64%α +0.64% · $3.16
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1, showing AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice. The data support the multi-component vaccine concept but is preclinical, no new clinical milestones, no regulatory action, and no financial figures were disclosed in the press release.
Key Facts
- Data presented at International Herpesvirus Workshop 2026 in Montreal
- New data show AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
- EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV vaccine antigens
- No licensed CMV vaccine exists currently
- No financial data, clinical trial results, or regulatory milestones mentioned
Financial Impact
No financial figures disclosed; preclinical data only, no revenue or earnings impact
Risk Factors
- EVX-V1 is preclinical, years away from potential approval and commercialization
- No CMV vaccine has been approved despite decades of research, highlighting high scientific risk
- Company has no disclosed revenue stream and requires additional capital to advance pipeline
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3325846 |
Track record
50 reports on EVAX
7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
- Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
- Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
- Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
- Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
- Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers